Consistent with our observation of poor patient survival due to ZEB1 deletion (Fig. 1b,c); patients with low ZEB1 expression resulted in shorter patient survival in both lower grade gliomas (***P < 0.0001, Fig. 3c) and GBMs (*P = 0.002, Fig. 3b). The gene discussed is ZEB1; the disease is central nervous system cancer.